This content is machine translated European Society of Cardiology Annual Congress 2021 Evolocumab provides additional benefit for maximal LDL-C reduction “The lower the better” is an important principle for lipid-lowering therapies, and PCSK9 monoclonal antibodies (PCSK9 mAb), such as evolocumab, can effectively lower LDL-C levels [1]. Data from the ECARA…
View Post 3 min This content is machine translated Primary hyperaldosteronism Therapy-resistant hypertension: clarify for Conn syndrome! If high blood pressure cannot be adequately controlled despite antihypertensive drugs, this may be due to undetected hormonal causes. Hypertension due to primary hyperaldosteronism, also known as “Conn syndrome,” is…
View Post 5 min This content is machine translated The metabolic patient Type 2 diabetes: reducing cardiovascular risk through lipid lowering Diabetes is associated with increased cardiovascular risk. Multifactorial therapy of the four major risk factors of blood glucose, weight, hypertension, and dyslipidemia in individuals with type 2 diabetes is challenging.…
View Post 6 min This content is machine translated Despite Corona emergency Do not ignore warning signals from the heart With the current dramatic rise in SARS-CoV-2 infections and the associated emergency in hospitals and intensive care units, heart specialists fear that cardiac patients with acute heart conditions may once…
View Post 3 min This content is machine translated Heart failure HFrEF – the four pillars of modern pharmacotherapy Chronic heart failure is one of the leading causes of death and reasons for hospitalization in developed countries. The prognosis is often poor – within five years, about half of…
View Post 4 min This content is machine translated Heart Health Focus on prevention, diagnosis and management of cardiovascular diseases Exciting questions and current research findings related to heart health were discussed at this year’s ESC. The main focus was on prevention strategies, diagnostics and the management of cardiovascular diseases.…
View Post 10 min This content is machine translated New AGLA guidelines Dyslipidemia – when to see a specialist? “The lower the better” – the approach to lower cholesterol levels as much as possible in patients at cardiovascular risk is more relevant than ever, according to the update of… CME-Test
View Post 2 min This content is machine translated Forecast improvement within reach Successful HFpEF therapy for the first time Prof. Stefan Anker, MD, provides a summary overview of the key outcomes of the EMPEROR-Preserved study.
View Post 2 min This content is machine translated Heart failure SGTL2 inhibitor shows clinically meaningful effect in HFpEF. Diastolic heart failure is the spectre of cardiology. To date, there is no conclusive therapy concept that improves the poor prognosis of those affected. Many hopeful treatment approaches were investigated and…
View Post 4 min This content is machine translated Hypercholesterolemia Bempedoic acid closes “gap” in lipid-lowering field Treatment with statins is part of the standard therapy for high cholesterol levels. However, a substantial proportion of patients on statin therapy alone do not achieve the LDL-C levels specified…
View Post 3 min This content is machine translated Heart attack and Co. Young infarct patients and atrial fibrillation – new insights The annual congress of the European Society of Cardiology again had a number of exciting and goal-oriented findings in store. In addition to groundbreaking study results in diastolic heart failure,…
